• Cerevance

  Participated · Series B · Apr 2024

  Cerevance uses a proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify drug targets expressed in specific human brain cell types. Its lead investigational candidate, solengepras (CVN424), is a once-daily oral therapy being evaluated in the pivotal Phase 3 ARISE trial, which is fully enrolled with 341 patients. ARISE is a randomized, double-blind, placebo-controlled study assessing solengepras as an adjunctive therapy in patients with motor fluctuations; topline data are expected at the end of Q3 2026. The company also is developing CVN293, a selective oral inhibitor targeting THIK1 (KCNK13). Cerevance announced an oversubscribed $20 million Series C to fund operations through the ARISE readout and to advance its pipeline, extending runway into mid-2027. The company is clinical-stage and based in Boston.

No current team members are available.